{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:41:21Z","timestamp":1785156081136,"version":"3.55.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-01373-9","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T14:48:41Z","timestamp":1747752521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Role of circulating MicroRNAs in prostate cancer diagnosis and risk stratification in the MCC Spain study"],"prefix":"10.1038","volume":"15","author":[{"given":"In\u00e9s","family":"G\u00f3mez-Acebo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Valero-Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Alonso-Molero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thal\u00eda","family":"Belmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Casta\u00f1o-Vinyals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Molina-Barcel\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Marcos-Gragera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manolis","family":"Kogevinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paz","family":"Rodr\u00edguez-Cund\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Alguacil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"P\u00e9rez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Poll\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinidad","family":"Dierssen-Sotos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"1373_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren, O. et al. 2022 Update on prostate Cancer epidemiology and risk Factors-A systematic review. Eur. Urol. 84, 191\u2013206 (2023).","journal-title":"Eur. Urol."},{"key":"1373_CR2","unstructured":"WHO. G. Cancer Today. (2022). https:\/\/gco.iarc.who.int\/today\/"},{"key":"1373_CR3","unstructured":"AECC, A. espa\u00f1ola contra el c\u00e1ncer. Dimensiones del c\u00e1ncer | AECC Observatorio. (2025). https:\/\/observatorio.contraelcancer.es\/explora\/dimensiones-del-cancer"},{"key":"1373_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.canlet.2021.10.011","volume":"524","author":"V Mugoni","year":"2022","unstructured":"Mugoni, V., Ciani, Y., Nardella, C. & Demichelis, F. Circulating RNAs in prostate cancer patients. Cancer Lett. 524, 57\u201369 (2022).","journal-title":"Cancer Lett."},{"key":"1373_CR5","doi-asserted-by":"publisher","first-page":"8994","DOI":"10.1038\/s41598-017-09386-9","volume":"7","author":"I G\u00f3mez-Acebo","year":"2017","unstructured":"G\u00f3mez-Acebo, I. et al. Risk model for prostate Cancer using environmental and genetic factors in the Spanish Multi-Case-Control (MCC) study. Sci. Rep. 7, 8994 (2017).","journal-title":"Sci. Rep."},{"key":"1373_CR6","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/ijc.29400","volume":"137","author":"K Papantoniou","year":"2015","unstructured":"Papantoniou, K. et al. Night shift work, chronotype and prostate cancer risk in the MCC-Spain case-control study. Int. J. Cancer. 137, 1147\u20131157 (2015).","journal-title":"Int. J. Cancer"},{"key":"1373_CR7","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s11912-024-01614-6","volume":"26","author":"MNE Almeeri","year":"2024","unstructured":"Almeeri, M. N. E., Awies, M. & Constantinou, C. Prostate cancer, pathophysiology and recent developments in management: A narrative review. Curr. Oncol. Rep. 26, 1511\u20131519 (2024).","journal-title":"Curr. Oncol. Rep."},{"key":"1373_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard, C. C. et al. Inherited DNA-Repair gene mutations in men with metastatic prostate Cancer. N Engl. J. Med. 375, 443\u2013453 (2016).","journal-title":"N Engl. J. Med."},{"key":"1373_CR9","first-page":"617","volume":"31","author":"F Urabe","year":"2024","unstructured":"Urabe, F. et al. Prostate cancer and liquid biopsies: clinical applications and challenges. Int. J. Urol. Off J. Jpn Urol. Assoc. 31, 617\u2013626 (2024).","journal-title":"Int. J. Urol. Off J. Jpn Urol. Assoc."},{"key":"1373_CR10","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.clnu.2021.02.033","volume":"40","author":"D Romaguera","year":"2021","unstructured":"Romaguera, D. et al. Consumption of ultra-processed foods and drinks and colorectal, breast, and prostate cancer. Clin. Nutr. 40, 1537\u20131545 (2021).","journal-title":"Clin. Nutr."},{"key":"1373_CR11","first-page":"5730","volume":"27","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha, M. et al. Prostate Cancer review: genetics, diagnosis, treatment options, and alternative approaches. Mol. Basel Switz. 27, 5730 (2022).","journal-title":"Mol. Basel Switz."},{"key":"1373_CR12","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/ijms19030904","volume":"19","author":"CA Wade","year":"2018","unstructured":"Wade, C. A. & Kyprianou, N. Profiling prostate Cancer therapeutic resistance. Int. J. Mol. Sci. 19, 904 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"1373_CR13","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.3390\/curroncol30020178","volume":"30","author":"CV Berenguer","year":"2023","unstructured":"Berenguer, C. V., Pereira, F., C\u00e2mara, J. S. & Pereira, J. A. M. Underlying features of prostate Cancer-Statistics, risk factors, and emerging methods for its diagnosis. Curr. Oncol. Tor. Ont. 30, 2300\u20132321 (2023).","journal-title":"Curr. Oncol. Tor. Ont."},{"key":"1373_CR14","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.3390\/cancers14246094","volume":"14","author":"S Eickelschulte","year":"2022","unstructured":"Eickelschulte, S. et al. Biomarkers for the detection and risk stratification of aggressive prostate Cancer. Cancers 14, 6094 (2022).","journal-title":"Cancers"},{"key":"1373_CR15","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.3390\/ijms24032185","volume":"24","author":"BE Boehm","year":"2023","unstructured":"Boehm, B. E., York, M. E., Petrovics, G., Kohaar, I. & Chesnut, G. T. Biomarkers of aggressive prostate Cancer at diagnosis. Int. J. Mol. Sci. 24, 2185 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1373_CR16","doi-asserted-by":"publisher","first-page":"175628722211039","DOI":"10.1177\/17562872221103988","volume":"14","author":"MW Farha","year":"2022","unstructured":"Farha, M. W. & Salami, S. S. Biomarkers for prostate cancer detection and risk stratification. Ther. Adv. Urol. 14, 17562872221103988 (2022).","journal-title":"Ther. Adv. Urol."},{"key":"1373_CR17","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/bju.14692","volume":"123","author":"A Light","year":"2019","unstructured":"Light, A., Elhage, O., Marconi, L. & Dasgupta, P. Prostate cancer screening: where are we now? BJU Int. 123, 916\u2013917 (2019).","journal-title":"BJU Int."},{"key":"1373_CR18","first-page":"2697","volume":"13","author":"L Cereser","year":"2023","unstructured":"Cereser, L., Evangelista, L., Giannarini, G. & Girometti, R. Prostate MRI and PSMA-PET in the primary diagnosis of prostate Cancer. Diagn. Basel Switz. 13, 2697 (2023).","journal-title":"Diagn. Basel Switz."},{"key":"1373_CR19","doi-asserted-by":"publisher","first-page":"154618","DOI":"10.1016\/j.prp.2023.154618","volume":"248","author":"A Azani","year":"2023","unstructured":"Azani, A. et al. MicroRNAs as biomarkers for early diagnosis, targeting and prognosis of prostate cancer. Pathol. - Res. Pract. 248, 154618 (2023).","journal-title":"Pathol. - Res. Pract."},{"key":"1373_CR20","doi-asserted-by":"publisher","first-page":"154591","DOI":"10.1016\/j.prp.2023.154591","volume":"248","author":"J Gupta","year":"2023","unstructured":"Gupta, J. et al. Angiogenesis and prostate cancer: MicroRNAs comes into view. Pathol. Res. Pract. 248, 154591 (2023).","journal-title":"Pathol. Res. Pract."},{"key":"1373_CR21","doi-asserted-by":"publisher","first-page":"147761","DOI":"10.1016\/j.gene.2023.147761","volume":"888","author":"MM Khan","year":"2023","unstructured":"Khan, M. M., Sharma, V. & Serajuddin, M. Emerging role of MiRNA in prostate cancer: A future era of diagnostic and therapeutics. Gene 888, 147761 (2023).","journal-title":"Gene"},{"key":"1373_CR22","doi-asserted-by":"publisher","first-page":"11502","DOI":"10.3390\/ijms231911502","volume":"23","author":"A Menon","year":"2022","unstructured":"Menon, A., Abd-Aziz, N., Khalid, K., Poh, C. L. & Naidu, R. MiRNA: A promising therapeutic target in Cancer. Int. J. Mol. Sci. 23, 11502 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1373_CR23","doi-asserted-by":"publisher","first-page":"101542","DOI":"10.1016\/j.tranon.2022.101542","volume":"26","author":"M Bilal","year":"2022","unstructured":"Bilal, M., Javaid, A., Amjad, F., Youssif, T. A. & Afzal, S. An overview of prostate cancer (PCa) diagnosis: potential role of MiRNAs. Transl Oncol. 26, 101542 (2022).","journal-title":"Transl Oncol."},{"key":"1373_CR24","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.eururo.2015.12.054","volume":"70","author":"L Fabris","year":"2016","unstructured":"Fabris, L. et al. The potential of MicroRNAs as prostate Cancer biomarkers. Eur. Urol. 70, 312\u2013322 (2016).","journal-title":"Eur. Urol."},{"key":"1373_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/ncrna8020025","volume":"8","author":"A Sreekumar","year":"2022","unstructured":"Sreekumar, A. & Saini, S. Role of MicroRNAs in neuroendocrine prostate Cancer. Non-Coding RNA. 8, 25 (2022).","journal-title":"Non-Coding RNA"},{"key":"1373_CR26","doi-asserted-by":"publisher","first-page":"12797","DOI":"10.3390\/ijms241612797","volume":"24","author":"G Rafikova","year":"2023","unstructured":"Rafikova, G., Gilyazova, I., Enikeeva, K., Pavlov, V. & Kzhyshkowska, J. Prostate cancer: genetics, epigenetics and the need for immunological biomarkers. Int. J. Mol. Sci. 24, 12797 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1373_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12967-019-1920-5","volume":"17","author":"C Hoey","year":"2019","unstructured":"Hoey, C. et al. Circulating MiRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy. J. Transl Med. 17, 173 (2019).","journal-title":"J. Transl Med."},{"key":"1373_CR28","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3390\/biomedicines9060646","volume":"9","author":"LJ Mart\u00ednez-Gonz\u00e1lez","year":"2021","unstructured":"Mart\u00ednez-Gonz\u00e1lez, L. J. et al. Identification of MicroRNAs as viable aggressiveness biomarkers for prostate Cancer. Biomedicines 9, 646 (2021).","journal-title":"Biomedicines"},{"key":"1373_CR29","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s12672-024-01376-4","volume":"15","author":"F Yuan","year":"2024","unstructured":"Yuan, F., Hu, Y., Lei, Y. & Jin, L. Recent progress in MicroRNA research for prostate cancer. Discov Oncol. 15, 480 (2024).","journal-title":"Discov Oncol."},{"key":"1373_CR30","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.gaceta.2014.12.003","volume":"29","author":"G Casta\u00f1o-Vinyals","year":"2015","unstructured":"Casta\u00f1o-Vinyals, G. et al. Population-based multicase-control study in common tumors in Spain (MCC-Spain): rationale and study design. Gac Sanit. 29, 308\u2013315 (2015).","journal-title":"Gac Sanit."},{"key":"1373_CR31","doi-asserted-by":"publisher","first-page":"e031904","DOI":"10.1136\/bmjopen-2019-031904","volume":"9","author":"J Alonso-Molero","year":"2019","unstructured":"Alonso-Molero, J. et al. Cohort profile: the MCC-Spain follow-up on colorectal, breast and prostate cancers: study design and initial results. BMJ Open. 9, e031904 (2019).","journal-title":"BMJ Open."},{"key":"1373_CR32","first-page":"347","volume":"75","author":"KP Seputra","year":"2021","unstructured":"Seputra, K. P., Purnomo, B. B., Susianti, H., Kalim, H. & Purnomo, A. F. miRNA-21 as reliable serum diagnostic biomarker candidate for metastatic progressive prostate cancer: Meta-analysis approach. Med. Arch. Sarajevo Bosnia Herzeg. 75, 347\u2013350 (2021).","journal-title":"Med. Arch. Sarajevo Bosnia Herzeg"},{"key":"1373_CR33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.acuro.2021.05.010","volume":"46","author":"WT Zhang","year":"2022","unstructured":"Zhang, W. T., Zhang, G. X., Zhao, R. Z. & Gao, S. S. The potential diagnostic accuracy of Circulating MicroRNAs for prostate cancer: A meta-analysis. Actas Urol. Esp. 46, 138\u2013149 (2022).","journal-title":"Actas Urol. Esp."},{"key":"1373_CR34","doi-asserted-by":"publisher","first-page":"BSR20211972","DOI":"10.1042\/BSR20211972","volume":"42","author":"MYC Stafford","year":"2022","unstructured":"Stafford, M. Y. C., Willoughby, C. E., Walsh, C. P. & McKenna, D. J. Prognostic value of miR-21 for prostate cancer: a systematic review and meta-analysis. Biosci. Rep. 42, BSR20211972 (2022).","journal-title":"Biosci. Rep."},{"key":"1373_CR35","first-page":"529","volume":"58","author":"D Nitusca","year":"2022","unstructured":"Nitusca, D. et al. Diagnostic value of microRNA-375 as future biomarker for prostate Cancer detection: A Meta-Analysis. Med. Kaunas Lith. 58, 529 (2022).","journal-title":"Med. Kaunas Lith."},{"key":"1373_CR36","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.euf.2018.01.008","volume":"5","author":"F Greco","year":"2019","unstructured":"Greco, F. et al. The potential role of MicroRNAs as biomarkers in benign prostatic hyperplasia: A systematic review and Meta-analysis. Eur. Urol. Focus. 5, 497\u2013507 (2019).","journal-title":"Eur. Urol. Focus"},{"key":"1373_CR37","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41416-021-01677-3","volume":"126","author":"S Rana","year":"2022","unstructured":"Rana, S., Valbuena, G. N., Curry, E., Bevan, C. L. & Keun, H. C. MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data. Br. J. Cancer. 126, 502\u2013513 (2022).","journal-title":"Br. J. Cancer"},{"key":"1373_CR38","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1007\/s11033-021-06568-7","volume":"48","author":"A Karadag","year":"2021","unstructured":"Karadag, A. et al. Identification of MiRNA signatures and their therapeutic potentials in prostate cancer. Mol. Biol. Rep. 48, 5531\u20135539 (2021).","journal-title":"Mol. Biol. Rep."},{"key":"1373_CR39","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.3390\/cancers13102433","volume":"13","author":"P Gandellini","year":"2021","unstructured":"Gandellini, P. et al. Prediction of grade reclassification of prostate Cancer patients on active surveillance through the combination of a Three-miRNA signature and selected clinical variables. Cancers 13, 2433 (2021).","journal-title":"Cancers"},{"key":"1373_CR40","doi-asserted-by":"publisher","first-page":"155798832211209","DOI":"10.1177\/15579883221120989","volume":"16","author":"F Bergez-Hern\u00e1ndez","year":"2022","unstructured":"Bergez-Hern\u00e1ndez, F. et al. Expression analysis of MiRNAs and their potential role as biomarkers for prostate Cancer detection. Am. J. Mens Health. 16, 15579883221120989 (2022).","journal-title":"Am. J. Mens Health"},{"key":"1373_CR41","first-page":"177","volume":"15","author":"VH Schitcu","year":"2022","unstructured":"Schitcu, V. H. et al. MicroRNA dysregulation in prostate Cancer. Pharmacogenomics Pers. Med. 15, 177\u2013193 (2022).","journal-title":"Pharmacogenomics Pers. Med."},{"key":"1373_CR42","doi-asserted-by":"publisher","first-page":"e11441","DOI":"10.7717\/peerj.11441","volume":"9","author":"S Zhang","year":"2021","unstructured":"Zhang, S. et al. MicroRNA panel in serum reveals novel diagnostic biomarkers for prostate cancer. PeerJ 9, e11441 (2021).","journal-title":"PeerJ"},{"key":"1373_CR43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13046-021-01875-0","volume":"40","author":"S Giglio","year":"2021","unstructured":"Giglio, S. et al. A preliminary study of micro-RNAs as minimally invasive biomarkers for the diagnosis of prostate cancer patients. J. Exp. Clin. Cancer Res. CR. 40, 79 (2021).","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"1373_CR44","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.3390\/cancers14102388","volume":"14","author":"Y Koh","year":"2022","unstructured":"Koh, Y. et al. Urine Cell-Free MicroRNAs in localized prostate Cancer patients. Cancers 14, 2388 (2022).","journal-title":"Cancers"},{"key":"1373_CR45","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.3906\/sag-2010-183","volume":"51","author":"S Hasano\u011flu","year":"2021","unstructured":"Hasano\u011flu, S. et al. Investigating differential MiRNA expression profiling using serum and urine specimens for detecting potential biomarkers for early prostate cancer diagnosis. Turk. J. Med. Sci. 51, 1764\u20131774 (2021).","journal-title":"Turk. J. Med. Sci."},{"key":"1373_CR46","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3389\/fonc.2019.00900","volume":"9","author":"D Bidarra","year":"2019","unstructured":"Bidarra, D. et al. Circulating MicroRNAs as biomarkers for prostate Cancer detection and metastasis development prediction. Front. Oncol. 9, 900 (2019).","journal-title":"Front. Oncol."},{"key":"1373_CR47","doi-asserted-by":"crossref","unstructured":"Lyu, J. et al. Discovery and validation of serum MicroRNAs as early diagnostic biomarkers for prostate Cancer in Chinese population. BioMed. Res. Int. 9306803 2019 (2019).","DOI":"10.1155\/2019\/9306803"},{"key":"1373_CR48","doi-asserted-by":"publisher","first-page":"e13384","DOI":"10.1111\/and.13384","volume":"51","author":"NH Ibrahim","year":"2019","unstructured":"Ibrahim, N. H., Abdellateif, M. S., Kassem, S. H. A., Abd El Salam, M. A. & El Gammal, M. M. Diagnostic significance of miR-21, miR-141, miR-18a and miR-221 as novel biomarkers in prostate cancer among Egyptian patients. Andrologia 51, e13384 (2019).","journal-title":"Andrologia"},{"key":"1373_CR49","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1007\/s11033-021-06384-z","volume":"48","author":"M Damodaran","year":"2021","unstructured":"Damodaran, M. et al. Differentially expressed miR-20, miR-21, miR-100, miR-125a and miR-146a as a potential biomarker for prostate cancer. Mol. Biol. Rep. 48, 3349\u20133356 (2021).","journal-title":"Mol. Biol. Rep."},{"key":"1373_CR50","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3390\/cancers13092068","volume":"13","author":"I Abramovic","year":"2021","unstructured":"Abramovic, I. et al. MiR-182-5p and miR-375-3p have higher performance than PSA in discriminating prostate Cancer from benign prostate hyperplasia. Cancers 13, 2068 (2021).","journal-title":"Cancers"},{"key":"1373_CR51","first-page":"e2022089","volume":"93","author":"D Canatan","year":"2022","unstructured":"Canatan, D. et al. Use of MicroRNAs as biomarkers in the early diagnosis of prostate cancer. Acta Bio-Medica Atenei Parm. 93, e2022089 (2022).","journal-title":"Acta Bio-Medica Atenei Parm"},{"key":"1373_CR52","doi-asserted-by":"publisher","first-page":"628094","DOI":"10.3389\/fonc.2021.628094","volume":"11","author":"S Rajendiran","year":"2021","unstructured":"Rajendiran, S. et al. MicroRNA-940 as a potential serum biomarker for prostate Cancer. Front. Oncol. 11, 628094 (2021).","journal-title":"Front. Oncol."},{"key":"1373_CR53","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1038\/s41467-021-23497-y","volume":"12","author":"S Cai","year":"2021","unstructured":"Cai, S. et al. Single-molecule amplification-free multiplexed detection of Circulating MicroRNA cancer biomarkers from serum. Nat. Commun. 12, 3515 (2021).","journal-title":"Nat. Commun."},{"key":"1373_CR54","first-page":"188","volume":"10","author":"J Freds\u00f8e","year":"2020","unstructured":"Freds\u00f8e, J. et al. Profiling of Circulating MicroRNAs in prostate Cancer reveals diagnostic biomarker potential. Diagn. Basel Switz. 10, 188 (2020).","journal-title":"Diagn. Basel Switz."},{"key":"1373_CR55","first-page":"564","volume":"55","author":"IA Paunescu","year":"2019","unstructured":"Paunescu, I. A. et al. Biomarker potential of plasma MicroRNA-150-5p in prostate Cancer. Med. Kaunas Lith. 55, 564 (2019).","journal-title":"Med. Kaunas Lith."},{"key":"1373_CR56","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1158\/1078-0432.CCR-18-2849","volume":"25","author":"F Urabe","year":"2019","unstructured":"Urabe, F. et al. Large-scale Circulating MicroRNA profiling for the liquid biopsy of prostate Cancer. Clin. Cancer Res. Off J. Am. Assoc. Cancer Res. 25, 3016\u20133025 (2019).","journal-title":"Clin. Cancer Res. Off J. Am. Assoc. Cancer Res."},{"key":"1373_CR57","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.3390\/cancers15164148","volume":"15","author":"M Cruz-Burgos","year":"2023","unstructured":"Cruz-Burgos, M. et al. Unraveling the role of EV-Derived miR-150-5p in prostate Cancer metastasis and its association with High-Grade Gleason scores: implications for diagnosis. Cancers 15, 4148 (2023).","journal-title":"Cancers"},{"key":"1373_CR58","doi-asserted-by":"publisher","first-page":"155050","DOI":"10.1016\/j.prp.2023.155050","volume":"254","author":"K Kookli","year":"2024","unstructured":"Kookli, K. et al. Role of microRNA-146a in cancer development by regulating apoptosis. Pathol. - Res. Pract. 254, 155050 (2024).","journal-title":"Pathol. - Res. Pract."},{"key":"1373_CR59","doi-asserted-by":"publisher","first-page":"155522","DOI":"10.1016\/j.prp.2024.155522","volume":"262","author":"Z Dobrijevi\u0107","year":"2024","unstructured":"Dobrijevi\u0107, Z. et al. Diagnostic properties of miR-146a-5p from liquid biopsies in prostate cancer: A meta-analysis. Pathol. Res. Pract. 262, 155522 (2024).","journal-title":"Pathol. Res. Pract."},{"key":"1373_CR60","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/gb-2010-11-3-r25","volume":"11","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).","journal-title":"Genome Biol."},{"key":"1373_CR61","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3102\/10769986025001060","volume":"25","author":"Y Benjamini","year":"2000","unstructured":"Benjamini, Y. & Hochberg, Y. On the adaptive control of the false discovery rate in multiple testing with independent statistics. J. Educ. Behav. Stat. 25, 60\u201383 (2000).","journal-title":"J. Educ. Behav. Stat."},{"key":"1373_CR62","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani, R. Regression shrinkage and selection via the Lasso. J. R Stat. Soc. Ser. B Methodol. 58, 267\u2013288 (1996).","journal-title":"J. R Stat. Soc. Ser. B Methodol."},{"key":"1373_CR63","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3390\/cancers14071625","volume":"14","author":"A Alwhaibi","year":"2022","unstructured":"Alwhaibi, A. et al. Regulation of Let-7a-5p and miR-199a-5p expression by Akt1 modulates prostate Cancer Epithelial-to-Mesenchymal transition via the transforming growth Factor-\u03b2 pathway. Cancers 14, 1625 (2022).","journal-title":"Cancers"},{"key":"1373_CR64","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/kjm2.12758","volume":"39","author":"S Hu","year":"2023","unstructured":"Hu, S. et al. miR-199a\/214 cluster enhances prostate cancer sensitiveness to nimotuzumab via targeting TBL1XR1. Kaohsiung J. Med. Sci. 39, 1178\u20131189 (2023).","journal-title":"Kaohsiung J. Med. Sci."},{"key":"1373_CR65","doi-asserted-by":"publisher","first-page":"83523","DOI":"10.18632\/oncotarget.18315","volume":"8","author":"J Zhong","year":"2017","unstructured":"Zhong, J. et al. Downregulation of miR-199a-5p promotes prostate adeno-carcinoma progression through loss of its Inhibition of HIF-1\u03b1. Oncotarget 8, 83523\u201383538 (2017).","journal-title":"Oncotarget"},{"key":"1373_CR66","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41419-020-2587-9","volume":"11","author":"JC Tseng","year":"2020","unstructured":"Tseng, J. C. et al. ROR2 suppresses metastasis of prostate cancer via regulation of miR-199a-5p-PIAS3-AKT2 signaling axis. Cell. Death Dis. 11, 376 (2020).","journal-title":"Cell. Death Dis."},{"key":"1373_CR67","doi-asserted-by":"publisher","first-page":"988794","DOI":"10.3389\/fonc.2022.988794","volume":"12","author":"B Luo","year":"2022","unstructured":"Luo, B. et al. microRNA-145-5p inhibits prostate cancer bone metastatic by modulating the epithelial-mesenchymal transition. Front. Oncol. 12, 988794 (2022).","journal-title":"Front. Oncol."},{"key":"1373_CR68","doi-asserted-by":"crossref","unstructured":"Sun, J., Deng, L. & Gong, Y. MiR-145-5p Inhibits the Invasion of Prostate Cancer and Induces Apoptosis by Inhibiting WIP1. J. Oncol. 4412705 (2021). (2021).","DOI":"10.1155\/2021\/4412705"},{"key":"1373_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1049\/syb2.12011","volume":"15","author":"ZG Huang","year":"2021","unstructured":"Huang, Z. G. et al. MiRNA-145-5p expression and prospective molecular mechanisms in the metastasis of prostate cancer. IET Syst. Biol. 15, 1\u201313 (2021).","journal-title":"IET Syst. Biol."},{"key":"1373_CR70","doi-asserted-by":"publisher","first-page":"790621","DOI":"10.3389\/fgene.2022.790621","volume":"13","author":"S Ji","year":"2022","unstructured":"Ji, S. et al. miR-145-5p inhibits neuroendocrine differentiation and tumor growth by regulating the SOX11\/MYCN Axis in prostate cancer. Front. Genet. 13, 790621 (2022).","journal-title":"Front. Genet."},{"key":"1373_CR71","doi-asserted-by":"publisher","first-page":"596826","DOI":"10.3389\/fgene.2020.596826","volume":"11","author":"Y Lin","year":"2020","unstructured":"Lin, Y. et al. Identification of key MicroRNAs and mechanisms in prostate Cancer evolution based on biomarker prioritization model and carcinogenic survey. Front. Genet. 11, 596826 (2020).","journal-title":"Front. Genet."},{"key":"1373_CR72","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12935-019-0933-8","volume":"19","author":"S Manvati","year":"2019","unstructured":"Manvati, S. et al. miR-145 supports cancer cell survival and shows association with DDR genes, methylation pattern, and epithelial to mesenchymal transition. Cancer Cell. Int. 19, 230 (2019).","journal-title":"Cancer Cell. Int."},{"key":"1373_CR73","doi-asserted-by":"publisher","first-page":"e18432","DOI":"10.1097\/MD.0000000000018432","volume":"99","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. Increased expression of microRNA-93 correlates with progression and prognosis of prostate cancer. Med. (Baltim). 99, e18432 (2020).","journal-title":"Med. (Baltim)."},{"key":"1373_CR74","doi-asserted-by":"publisher","first-page":"10463","DOI":"10.1002\/jcb.28332","volume":"120","author":"Y Yang","year":"2019","unstructured":"Yang, Y., Jia, B., Zhao, X., Wang, Y. & Ye, W. miR-93-5p May be an important oncogene in prostate cancer by bioinformatics analysis. J. Cell. Biochem. 120, 10463\u201310483 (2019).","journal-title":"J. Cell. Biochem."},{"key":"1373_CR75","doi-asserted-by":"publisher","first-page":"100073","DOI":"10.1016\/j.adcanc.2022.100073","volume":"6","author":"N Jafari","year":"2022","unstructured":"Jafari, N. et al. Novel plasma exosome biomarkers for prostate cancer progression in co-morbid metabolic disease. Adv. Cancer Biol. - Metastasis. 6, 100073 (2022).","journal-title":"Adv. Cancer Biol. - Metastasis"},{"key":"1373_CR76","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.7150\/jca.83863","volume":"14","author":"M Sun","year":"2023","unstructured":"Sun, M. et al. Activation of the HNRNPA2B1\/miR-93-5p\/FRMD6 axis facilitates prostate cancer progression in an m6A-dependent manner. J. Cancer. 14, 1242\u20131256 (2023).","journal-title":"J. Cancer"},{"key":"1373_CR77","first-page":"1803","volume":"11","author":"Y Lin","year":"2018","unstructured":"Lin, Y. et al. miR-24-3p stimulates migration, invasion and proliferation of prostate cancer cells by targeting suppressor of cytokine signaling 6. Int. J. Clin. Exp. Pathol. 11, 1803\u20131810 (2018).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"1373_CR78","first-page":"4668","volume":"25","author":"Y Cheng","year":"2021","unstructured":"Cheng, Y. et al. LncRNA HOXA11-AS promotes cell growth by sponging miR-24-3p to regulate JPT1 in prostate cancer. Eur. Rev. Med. Pharmacol. Sci. 25, 4668\u20134677 (2021).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"1373_CR79","doi-asserted-by":"publisher","first-page":"7545","DOI":"10.2147\/OTT.S119027","volume":"9","author":"G Cochetti","year":"2016","unstructured":"Cochetti, G. et al. Different levels of serum MicroRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role. OncoTargets Ther. 9, 7545\u20137553 (2016).","journal-title":"OncoTargets Ther."},{"key":"1373_CR80","doi-asserted-by":"publisher","first-page":"pbac001","DOI":"10.1093\/pcmedi\/pbac001","volume":"5","author":"Y Lin","year":"2022","unstructured":"Lin, Y., Qi, X., Chen, J. & Shen, B. Multivariate competing endogenous RNA network characterization for cancer MicroRNA biomarker discovery: a novel bioinformatics model with application to prostate cancer metastasis. Precis Clin. Med. 5, pbac001 (2022).","journal-title":"Precis Clin. Med."},{"key":"1373_CR81","first-page":"2802","volume":"11","author":"RB Duca","year":"2021","unstructured":"Duca, R. B. et al. MiR-19b-3p and miR-101-3p as potential biomarkers for prostate cancer diagnosis and prognosis. Am. J. Cancer Res. 11, 2802\u20132820 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"1373_CR82","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1080\/21655979.2021.1949513","volume":"12","author":"Z Gu","year":"2021","unstructured":"Gu, Z. et al. Inhibition of MicroRNA miR-101-3p on prostate cancer progression by regulating Cullin 4B (CUL4B) and PI3K\/AKT\/mTOR signaling pathways. Bioengineered 12, 4719\u20134735 (2021).","journal-title":"Bioengineered"},{"key":"1373_CR83","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12967-018-1506-7","volume":"16","author":"Y Lin","year":"2018","unstructured":"Lin, Y. et al. Biomarker MicroRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model. J. Transl Med. 16, 134 (2018).","journal-title":"J. Transl Med."},{"key":"1373_CR84","doi-asserted-by":"publisher","first-page":"574046","DOI":"10.3389\/fimmu.2020.574046","volume":"11","author":"C Niespolo","year":"2020","unstructured":"Niespolo, C. et al. Tribbles-1 expression and its function to control inflammatory cytokines, including Interleukin-8 levels are regulated by MiRNAs in macrophages and prostate Cancer cells. Front. Immunol. 11, 574046 (2020).","journal-title":"Front. Immunol."},{"key":"1373_CR85","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12885-018-5228-2","volume":"19","author":"X Qiu","year":"2019","unstructured":"Qiu, X. et al. Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells. BMC Cancer. 19, 27 (2019).","journal-title":"BMC Cancer"},{"key":"1373_CR86","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3390\/cancers14030532","volume":"14","author":"M Puhka","year":"2022","unstructured":"Puhka, M. et al. Exploration of extracellular vesicle MiRNAs, targeted mRNAs and pathways in prostate cancer: relation to disease status and progression. Cancers 14, 532 (2022).","journal-title":"Cancers"},{"key":"1373_CR87","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3892\/ijo.2017.3840","volume":"50","author":"Y Huang","year":"2017","unstructured":"Huang, Y. et al. Upregulation of miR-146a by YY1 depletion correlates with delayed progression of prostate cancer. Int. J. Oncol. 50, 421\u2013431 (2017).","journal-title":"Int. J. Oncol."},{"key":"1373_CR88","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1002\/pros.23068","volume":"75","author":"B Xu","year":"2015","unstructured":"Xu, B. et al. Hsa-miR-146a-5p modulates androgen-independent prostate cancer cells apoptosis by targeting ROCK1. Prostate 75, 1896\u20131903 (2015).","journal-title":"Prostate"},{"key":"1373_CR89","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.ajpath.2018.12.014","volume":"189","author":"B Baumann","year":"2019","unstructured":"Baumann, B. et al. Association of high miR-182 levels with Low-Risk prostate Cancer. Am. J. Pathol. 189, 911\u2013923 (2019).","journal-title":"Am. J. Pathol."},{"key":"1373_CR90","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/biom12020187","volume":"12","author":"MF Souza","year":"2022","unstructured":"Souza, M. F. et al. MiR-182-5p modulates prostate Cancer aggressive phenotypes by targeting EMT associated pathways. Biomolecules 12, 187 (2022).","journal-title":"Biomolecules"},{"key":"1373_CR91","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/pros.23825","volume":"79","author":"NO Kurul","year":"2019","unstructured":"Kurul, N. O. et al. The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease. Prostate 79, 1125\u20131132 (2019).","journal-title":"Prostate"},{"key":"1373_CR92","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.abb.2018.07.010","volume":"654","author":"J Yu","year":"2018","unstructured":"Yu, J., Feng, Y., Wang, Y. & An, R. Aryl hydrocarbon receptor enhances the expression of miR-150-5p to suppress in prostate cancer progression by regulating MAP3K12. Arch. Biochem. Biophys. 654, 47\u201354 (2018).","journal-title":"Arch. Biochem. Biophys."},{"key":"1373_CR93","first-page":"173","volume":"20","author":"L Dezhong","year":"2015","unstructured":"Dezhong, L. et al. miR-150 is a factor of survival in prostate cancer patients. J. BUON Off J. Balk. Union Oncol. 20, 173\u2013179 (2015).","journal-title":"J. BUON Off J. Balk. Union Oncol."},{"key":"1373_CR94","doi-asserted-by":"publisher","unstructured":"Zhao, Y., Zhu, Y. & Song, J. MiR-150 promotes the cell invasion of prostate cancer cells by directly regulating the expression of p53. https:\/\/www.ingentaconnect.com\/contentone\/govi\/pharmaz\/2016\/00000071\/00000009\/art00008 (2016). https:\/\/doi.org\/10.1691\/ph.2016.6645","DOI":"10.1691\/ph.2016.6645"},{"key":"1373_CR95","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/j.biopha.2018.09.029","volume":"109","author":"B Yang","year":"2019","unstructured":"Yang, B. et al. Downregulation of miR-139-5p promotes prostate cancer progression through regulation of SOX5. Biomed. Pharmacother Biomedecine Pharmacother. 109, 2128\u20132135 (2019).","journal-title":"Biomed. Pharmacother Biomedecine Pharmacother"},{"key":"1373_CR96","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/pros.23871","volume":"79","author":"RK Nam","year":"2019","unstructured":"Nam, R. K. et al. MicroRNA-139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL. Prostate 79, 1422\u20131438 (2019).","journal-title":"Prostate"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01373-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01373-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01373-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T15:06:13Z","timestamp":1747753573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01373-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1373"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-01373-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The studies involving human participants were reviewed and approved by CEIC 2018.280 and 2008\/3123\/I. The patients\/participants provided their written informed consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"17517"}}